Consensus $8.71. Raises FY23 revenue view to $8.93B-$9.08B from $8.83B-$9.03B, consensus $8.98B. Sees FY23 capital expenditures $400M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Reports First Quarter 2023 Financial Results; Updates Guidance for Full Year 2023
- Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
- Quest Diagnostics (DGX) Q1 Earnings Cheat Sheet
- Quest Diagnostics and NewYork-Presbyterian Complete Laboratory Services Acquisition
- Quest Diagnostics upgraded to Neutral from Sell at Citi